抑制剂
抑制剂 性质
| 密度 | 1.186±0.06 g/cm3(Predicted) |
|---|---|
| 储存条件 | -20° |
| 溶解度 | 溶于 DMSO (>25 mg/ml)。 |
| 形态 | 固体 |
| 酸度系数(pKa) | 3.91±0.40(Predicted) |
| 颜色 | 米白色 |
| 稳定性 | 自购买之日起 1 年内保持稳定。 DMSO 中的溶液可在 -20° 下保存长达 3 个月。 |
抑制剂 用途与合成方法
| Target | Value |
|
PTP1B
(Cell-free assay) | 0.28 μM |
In human hepatoma-derived cells (HepG2), KY-226 (0.3-10 μM) increases the phosphorylated insulin receptor (pIR) produced by insulin.
KY-226 (1 μM; 24 hours; bEnd.3 cells) treatment rescues lipopolysaccharide-induced reduction of mRNA and protein levels of ZO-1. KY-226 treatment restores phosphorylation of pAkt (T308) and its downstream target forkhead box protein O1 (FoxO1) (S256) in bEnd.3 cells.
Western Blot Analysis
| Cell Line: | bEnd.3 cells stimulated with LPS |
| Concentration: | 1 μM |
| Incubation Time: | 24 hours |
| Result: | Rescued lipopolysaccharide-induced reduction of mRNA and protein levels of ZO-1. |
KY-226 (10-30 mg/kg/day; oral administration; daily; for 4 weeks; male
db/db
mice) treatment significantly reduces plasma glucose and triglyceride levels as well as hemoglobin A1c values without increasing body weight gain.
KY-226 attenuates plasma glucose elevations in the oral glucose tolerance test. KY-226 also increases pIR and phosphorylated Akt in the liver and femoral muscle.
| Animal Model: | Male db/db mice (8-11 weeks old) |
| Dosage: | 10 mg/kg and 30 mg/kg |
| Administration: | Oral administration; daily; for 4 weeks |
| Result: | Significantly reduced plasma glucose and triglyceride levels as well as hemoglobin A1c values without increasing body weight gain. |
抑制剂 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-04-30 | HY-120327 | 1 mg | 920 | ||
| 2024-04-30 | HY-120327 | 抑制剂 | 1621673-53-7 | 5mg | 2300 |
